Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder

Journal of Clinical Psychopharmacology

Volumn 28, Issue 2, 2008, Pages 147-155

  Van Den Eynde, Frédérique ^a,b,d   Senturk, Vesile ^b   Naudts, Kris ^b   Vogels, Caroline ^c   Bernagie, Katrien ^a   Thas, Olivier ^a   Van Heeringen, Cornelis ^a   Audenaert, Kurt ^a  

^a GHENT UNIVERSITY   (Belgium)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Psychiatric Hospital St Camillus   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LORAZEPAM; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; AKATHISIA; ARTICLE; BORDERLINE STATE; CLINICAL ARTICLE; COGNITION; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; FEMALE; HOSPITAL PATIENT; HUMAN; HYPOTENSION; IMPULSIVENESS; MALE; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRIORITY JOURNAL; PSYCHOTHERAPY; SCORING SYSTEM; SEDATION; SIDE EFFECT; STRUCTURED QUESTIONNAIRE; XEROSTOMIA;

ADULT; AFFECTIVE SYMPTOMS; AGGRESSION; ANGER; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; DEPRESSION; DIBENZOTHIAZEPINES; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; HUMANS; IMPULSIVE BEHAVIOR; MALE; NEUROPSYCHOLOGICAL TESTS; PATIENT DROPOUTS; PATIENT SATISFACTION; RECEPTORS, DOPAMINE D2; SEX FACTORS; TEST ANXIETY SCALE; TREATMENT OUTCOME; XEROSTOMIA;

EID: 40949127907     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318166c4bf     Document Type: Article

References (75)

1. Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. Arch Gen Psychiatry. 2001;58:590-596.
2. Widiger TA, Frances AJ. Epidemiology, diagnosis, and comorbidity of borderline personality disorder. In: Tasman A, Hales RE, Frances AJ, eds. American Psychiatric Press. Review of Psychiatry, vol. 8. Washington, DC: American Psychiatric Press; 1989:8-24.
3. Widiger TA, Weismann MM. Epidemiology in borderline personality disorder. Hosp Community Psychiatry. 1991;42:1015-1021.
4. Binks CA, Fenton M, McCarthy L, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2006;25(1)[Art. No.: CD005653].
5. American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2001;158:1-52.
6. Skodol AE, Gunderson JG, Pfohl B, et al. The borderline diagnosis: I. Psychopathology, comorbidity, and personality structure. Biol Psychiatry. 2002;51:936-950.
7. Linehan MM. Cognitive-Behavioural Treatment of Borderline Personality Disorder. New York, NY: Guilford Press; 1993.
8. Links PS, Heslegrave R, van Reekum R. Impulsivity: core aspect of borderline personality disorder. J Personal Disord. 1999;13(1):1-9.
9. Coid JW. An affective syndrome in psychopaths with borderline personality disorder? Br J Psychiatry. 1993;162:641-650.
10. McGlashan TH, Grilo CM, Sanislow CA, et al. Two-year prevalence and stability of individual DSM-IV criteria for schizotypal, borderline, avoidant and obsessive-compulsive personality disorders: toward a hybrid model of Axis II disorders. Am J Psychiatry. 2005;162:883-889.
11. Oldham JM, Bender DS, Skodol AE, et al. Testing an APA practice guideline: symptom-targeted medication utilization for patients with BPD. J Psychiatr Pract. 2004;10:156-161.
12. Nose M, Cipriani A, Biancosino B, et al. Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2006;21:345-353.
13. Soloff PH, George A, Nathan RS, et al. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry. 1986;43:691-697.
14. Soloff PH, George A, Nathan RS, et al. Amitryptiline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol. 1989;9:238-246.
15. Cornelius JR, Soloff PH, Perel JM, et al. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry. 1993;150:1843-1848.
16. Schulz SC, Camlin KL, Berry SA, et al. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999;46:1429-1435.
17. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62:849-854.
18. Soler J, Pascual JC, Campins J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162:1221-1224.
19. Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as a target. J Clin Psychiatry. 2005;66:1298-1303.
20. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot-study. J Clin Psychiatry. 2006;67:1042-1046.
21. Perella M, Carrus D, Costa E, et al. Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:158-163.
22. Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behaviour. J Affect Disord. 1982;4:291-298.
23. Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163:833-838.
24. Chengappa KN, Ebeling T, Kang SJ. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry. 1999;60:477-484.
25. Benedetti F, Sforzini L, Colombo C, et al. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry. 1998;59:103-107.
26. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline personality disorder: a preliminary study. Compr Psychiatry. 1993;34:402-405.
27. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004;65:903-907.
28. Ricca P, Marchiaro L, Cocuzza E, et al. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry. 2002;63:241-244.
29. Bogenschutz MP, George NH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104-109.
30. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry. 2002;63(suppl 13):5-11.
31. Tandon RT. Improvement without impairment: a review of clinical data for quetiapine in the treatment of schizophrenia. J Clin Psychopharmacol. 2003;23(suppl 1):15-20.
32. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600-609.
33. Hilger E, Barnas C, Kasper S. Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry. 2003;4:42-44.
34. Adityanjee, Schultz SC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry. 2002;63(suppl 13):32-38.
35. Gunderson JG, Kolb JE, Austin V. Diagnostic interview for borderline patients. Am J Psychiatry. 1981;138(7):896-903.
36. Derksen JJL. Het diagnostisch interview voor borderline patiënten: handleiding (DIB). Lisse, Netherlands: Swets Test Services (STS); 1988.
37. Groenestijn MA, van Akkerhuis GW, Kupka RW, et al. SCID-I: Gestructureerd klinisch interview voor het vaststellen van DSM-IV stoornissen. Lisse, Netherlands: Swets Test Publishers; 1998.
38. Weertman A, Arntz A, Kerkhofs ML. Gestructureerd klinisch interview voor DSM-IV As II persoonlijkheidsstoornissen, SCID-II. Lisse, Netherlands: Swets Test Publishers; 2000.
39. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IVAxis I Disorders. New York, NY: Biometric Research, New York State Psychiatric Institute; 1996.
40. First MB, Gibbon M, Spitzer RL, et al. Structured Clinical Interview for DSM-IV Personality Disorders (SCIP-II). Washington, DC: American Psychiatric Press; 1996.
41. Barratt ES. Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychol Rep. 1965;16:547-545.
42. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt Impulsiveness Scale. J Clin Psychol. 1995;51:768-774.
43. Buss AH, Durkee A. An inventory for assessing different kinds of hostility. J Consult Psychol. 1957;21:343-349.
44. Lange A, Hoogendoorn M, Wiederspahn A, et al. Buss-Durkee Hostility Inventory: Handleiding, verantwoording en normezring van de Nederlands Buss-Durkee Agressievragenlijst. Lisse, Netherlands: Swets Test Services; 1995.
45. Spielberger C. State-Trait Anger Expression Inventory: Professional Manual. Odessa, FL: Psychological Assessment Resources; 1991.
46. Van der Ploeg HM, Defares PB, Spielberger CD. Handleiding bij de Zelf-Analyse Vragenlijst (ZAV). Een Nederlandse bewerking van de Spielberger State-Trait Anger Scale. Lisse, Netherlands: Swets & Zeitlinger; 1982.
47. Spielberger CD. Manual for the State-Trait Anxiety Inventory (Form Y) ("Self evaluation questionnaire"). Palo Alto, CA: Consulting Psychologists Press; 1983.
48. Van der Ploeg HM. Handleiding bij de Zelf Beoordelings Vragenlijst. Een Nederlandse bewerking van de Spielberger State-Trait Anxiety Inventory. Tweede gewijzigde druk. Lisse, Netherlands: Swets Test Publishers; 2000.
49. Beck AT, Steer RA. Manual for the Beck Depression Inventory. San Antonio, TX: The Psychological Corp; 1987.
50. van der Does AJW. De Nederlandse versie van de Beck Depression Inventory. 2nd ed. Lisse, Netherlands: Swets Test Publishers; 2002.
51. Harvey PD, Greenberg BR, Serper MR. The Affective Lability Scales: development, reliability and validity. J Clin Psychol. 1989;45:786-793.
52. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18:643-661.
53. Hammes JGW. De Stroop Kleur-Woord Test handleiding. Lisse, Netherlands: Swets & Zeitlinger; 1971.
54. Bechara A, Damasio AR, Damasio H, et al. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition. 1994;50:7-15.
55. Fertuck EA, Mark T, Lenzenweger F, et al. Executive neurocognition, memory systems, and borderline personality disorder. Clin Psychol Rev. 2006;26:346-375.
56. Bazanis E, Rogers RD, Dowson JH, et al. Neurocognitive deficits in decision making and planning of patients with DSM-III-R borderline personality disorder. Psychol Med. 2002;32,1395-1405.
57. Hochhausen NM, Lorenz AR, Newman JP. Specifying the impulsivity of female inmates with borderline personality disorder. J Abnorm Psychol. 2002;111(3):495-501.
58. Hollander E, Rosen J. Impulsivity. J Psychopharmacol. 2000;14:S39-S44.
59. Gueorguieva R, Krystal J. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry. 2004;61(3):310-317.
60. Henry C, Mitropoulou V, New AS, et al. Affective instability and impulsivity in borderline personality disorder and bipolar II disorders: similarities and differences. J Psychiatr Res. 2001;35:307-312.
61. Soloff PH, Lynch KG, Kelly TM, et al. Characteristics of suicide attempts of patients with major depressive episode and borderline personality disorder: a comparative study. Am J Psychiatry. 2000;157:601-608.
62. Perugi G, Toni C, Travierso MC, et al. The role of cyclothymia in atypical depression: toward a data-based reconceptualization of the borderline-bipolar II connection. J Affect Disord. 2003;73(1-2):87-98.
63. Mackinnon DF, Pies R. Affective instability as rapid cycling: theoretical and clinical implications for borderline personality and bipolar spectrum disorders. Bipolar Disord. 2006;8(1):1-14.
64. Koenigsberg HW, Harvey PD, Mitropoulou V, et al. Characterizing affective instability in borderline personality disorder. Am J Psychiatry. 2002;159:784-788.
65. Cowdry RW, Gardner DL, O'Leary KM, et al. Mood variability: a study of four groups. Am J Psychiatry. 1991;148:1505-1511.
66. Dando TM, Keating GM. Quetiapine: a review of its use in acute mania and depression associated with bipolar disorder. Drugs. 2005;65(17):2533- 2551.
67. Stanley B, Wilson ST. Heightened subjective experience of depression in borderline personality disorder. J Personal Disord. 2006;20(4):307-318.
68. Trull TJ, Widiger TA, Lynam DR, et al. Borderline personality disorder from the perspective of general personality functioning. J Abnorm Psychol. 2003;112(2):193-202.
69. Skodol AE, Bender DS. Why are women diagnosed borderline more than men? Psychiatr Q. 2003;74(4):349-360.
70. Johnson DM, Shea MT, Yen S, et al. Gender differences in borderline personality disorder: findings from the Collaborative Longitudinal Personality Disorders Study. Compr Psychiatry. 2003;44:284-292.
71. Sieswerda S, Arntz A, Mertens I, et al. Hypervigilance in patients with borderline personality disorder: specificity, automaticity, and predictors. Behav Res Ther. 2007;45(5):1011-1024.
72. Dom G, De Wilde, Hulstijn W, et al. Decision-making deficits in alcohol-dependent patients with and without comorbid personality disorder. Alcohol Clin Exp Res. 2006;30(10):1670-1677.
73. Harvey PD, Patterson TL, Potter LS, et al. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry. 2006;163(11):1918-1925.
74. de Geus F, Denys D, Westenberg H. Effects of quetiapine on cognitive functioning in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007;22:77-84.
75. Rinne T, van den Brink W, Wouters L, et al. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002;159:2048-2054.